IP Library Granted Patent US 9,835,616
Granted Patent B2
US 9,835,616 · App. 14/778,729 · Granted Dec 5, 2017

In vitro method for assessing cytokine storm responses

Inventor: Jane Alison Mitchell (London, GB)
Assignee: Imperial Innovations Ltd.
G01N33/5023G01N33/5047G01N2333/52
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,835,616
App. No.
14/778,729
Granted
Dec 5, 2017
Kind
B2
Abstract

The present disclosure an in vitro method of assaying the stimulation of a cytokine storm response comprising the steps of: a. co-culturing PBMCs and matched differentiated endothelial cells to provide a system representative of human responses in vivo, and b. exposing the co-cultured cell system to a test agent, c. analyzing the system for the presence of one or more cytokines released after exposing the co-culture system to said test agent, and d. optionally evaluating the response to the test agent in comparison to a response to one or more control agents.

Claims (15)

1. An in vitro method of assaying the stimulation of a cytokine storm response comprising:

(a) co-culturing peripheral blood mononuclear cells (PBMCs) and matched differentiated endothelial cells to provide a cell system representative of human responses in vivo;

(b) exposing the co-cultured cell system to a test agent;

(c) analyzing the system for presence of one or more cytokines released after exposing the co-culture system to the test agent; and

(d) optionally evaluating the response to the test agent in comparison to a response to one or more control agents;

wherein the endothelial cells are autologous to the PBMCs; and

wherein the endothelial cells are derived from blood outgrowth endothelial cells.

2. The method of claim 1 , wherein the endothelial cells are capable of being cultured to provide a phenotype; wherein the phenotype is characterized as elongated and aligned.

3. The method of claim 1 , wherein the response of the test agent is evaluated in comparison to one or more control agents.

4. The method of claim 3 , wherein the control agent is a TGN1412 anti-CD28 antibody or an anti-CD52 antibody.

5. The method of claim 4 , wherein the anti-CD52 antibody is alemtuzumab.

6. The method of claim 1 , wherein the analyzed cytokine is CXCL8.

7. The method of claim 1 , wherein exposing the co-cultured cell system to a test agent comprises exposing the co-cultured cell system to an agent which induces cytokine storm in the system, followed by the exposure of the system to a test inhibitor the induced response.

8. The method of claim 7 , further comprising identifying an inhibitor of cytokine storm in the in vitro co-cultured cell system.

9. The method of claim 4 , wherein the endothelial cells are from a biopsy.

Assignments (3)
CHANGE OF NAME Recorded Dec 4, 2019
From: IMPERIAL WHITE CITY INCUBATOR LIMITED
To: IMPERIAL COLLEGE INNOVATIONS LIMITED
Reel/Frame 051176/0757 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 22, 2019
From: IMPERIAL INNOVATIONS LIMITED
To: IMPERIAL WHITE CITY INCUBATOR LIMITED
Reel/Frame 051088/0855 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 8, 2017
From: MITCHELL, JANE ALISON
To: IMPERIAL INNOVATIONS LTD.
Reel/Frame 041509/0665 →
Priority Claims (2)
GB 1305318.6 · Mar 22, 2013 · national
GB 1309385.1 · May 24, 2013 · national
Continuity (1)
Related Publication 20160047795A1 · Feb 18, 2016